Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Porter

Showing results (661-670 of 764) with videos related to

Pageof 77
Sort By:
Circulation|December 1, 1996
Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database GroupR J Rodeheffer, D C Naftel, L W Stevenson, et al.
World Neurosurgery|December 29, 2019
Addressing Misdiagnosis of Optic Nerve Sheath MeningiomasBrian D Kalen, Ryan A Hess, Karl R Abi-Aad, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and SingaporeShehara M Mendis, Shawn Vasoo, Brian D Johnston, et al.
Blood|May 3, 2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok, Antonis Kattamis, M Domenica Cappellini, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical courseFrancois M Cady, Brian Patrick O'Neill, Mark E Law, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|April 27, 2010
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overloadJohn-Paul Carpenter, Francisco Alpendurada, Monica Deac, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Bioorganic & Medicinal Chemistry|August 11, 2010
Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteasesAnne-Marie R Dechert, James P MacNamara, Sarah R Breevoort, et al.
Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.
Pageof 77

Showing results (661-670 of 764) with videos related to

Sort By:
Pageof 77
Circulation|December 1, 1996
Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database GroupR J Rodeheffer, D C Naftel, L W Stevenson, et al.
World Neurosurgery|December 29, 2019
Addressing Misdiagnosis of Optic Nerve Sheath MeningiomasBrian D Kalen, Ryan A Hess, Karl R Abi-Aad, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Clinical and Molecular Correlates of Escherichia coli Bloodstream Infection from Two Geographically Diverse Centers in Rochester, Minnesota, and SingaporeShehara M Mendis, Shawn Vasoo, Brian D Johnston, et al.
Blood|May 3, 2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok, Antonis Kattamis, M Domenica Cappellini, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical courseFrancois M Cady, Brian Patrick O'Neill, Mark E Law, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|April 27, 2010
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overloadJohn-Paul Carpenter, Francisco Alpendurada, Monica Deac, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Bioorganic & Medicinal Chemistry|August 11, 2010
Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteasesAnne-Marie R Dechert, James P MacNamara, Sarah R Breevoort, et al.
Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.
Pageof 77